Akari Therapeutics (AKTX) Stock Forecast, Price Target & Predictions


OverviewOwnershipFinancialsChart

AKTX Stock Forecast


Akari Therapeutics stock forecast is as follows: an average price target of $12.00K (represents a 493727.16% upside from AKTX’s last price of $2.43) and

AKTX Price Target


Akari Therapeutics Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 05, 2022-H.C. Wainwright$12.00K$4.31K178.45%493727.16%
Row per page
Go to

The latest Akari Therapeutics stock forecast, released on Dec 05, 2022 by H.C. Wainwright company, set a price target of $12.00K, which represents a 178.45% increase from the stock price at the time of the forecast ($4.31K), and a 493727.16% increase from AKTX last price ($2.43).

Akari Therapeutics Price Target by Period


1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$2.43$2.43$2.43
Upside/Downside-100.00%-100.00%-100.00%

In the current month, the average price target of Akari Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Akari Therapeutics's last price of $2.43. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Akari Therapeutics Financial Forecast


Akari Therapeutics Revenue Forecast

Dec 24Sep 24Jun 24
Revenue---
Avg Forecast---
High Forecast---
Low Forecast---
# Analysts---
Surprise %---

Akari Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. AKTX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Akari Therapeutics EBITDA Forecast

Dec 24Sep 24Jun 24
# Analysts---
EBITDA---
Avg Forecast---
High Forecast---
Low Forecast---
Surprise %---

undefined analysts predict AKTX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Akari Therapeutics's previous annual EBITDA (undefined) of $NaN.

Akari Therapeutics Net Income Forecast

Dec 24Sep 24Jun 24
# Analysts---
Net Income---
Avg Forecast$-9.42M$-5.65M$-9.42M
High Forecast$-9.42M$-5.65M$-9.42M
Low Forecast$-9.42M$-5.65M$-9.42M
Surprise %---

Akari Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. AKTX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Akari Therapeutics SG&A Forecast

Dec 24Sep 24Jun 24
# Analysts---
SG&A---
Avg Forecast---
High Forecast---
Low Forecast---
Surprise %---

Akari Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to AKTX last annual SG&A of $NaN (undefined).

Akari Therapeutics EPS Forecast

Dec 24Sep 24Jun 24
# Analysts---
EPS---
Avg Forecast$-1.00$-0.60$-1.00
High Forecast$-1.00$-0.60$-1.00
Low Forecast$-1.00$-0.60$-1.00
Surprise %---

According to undefined Wall Street analysts, Akari Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to AKTX previous annual EPS of $NaN (undefined).

Akari Therapeutics Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
AKTXAkari Therapeutics$2.43$12.00K493727.16%-
PCSAProcessa Pharmaceuticals$1.11$9.00710.81%Buy
ANEBAnebulo Pharmaceuticals$1.89$6.00217.46%Buy
CAPRCapricor Therapeutics$18.60$35.7592.20%Buy
SLNOSoleno Therapeutics$56.14$76.0035.38%Buy
AXLAAxcella Health$4.58$6.0031.00%Buy

AKTX Forecast FAQ


According to Wall Street analysts' prediction for AKTX stock, the company can go up by 493727.16% (from the last price of $2.43 to the average price target of $12K), up by 493727.16% based on the highest stock price target, and up by 493727.16% based on the lowest stock price target.

AKTX's average twelve months analyst stock price target of $12K supports the claim that Akari Therapeutics can reach $4 in the near future.

AKTX's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-24.487M (high $-24.487M, low $-24.487M), average SG&A $0 (high $0, low $0), and average EPS is $-2.6 (high $-2.6, low $-2.6).